This Article Extract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schneider, D. J. Articles by Moore, J. W. Search for Related Content PubMed PubMed Citation Articles by Schneider, D. J. Articles by Moore, J. W. Related Collections Cardiovascular imaging agents/Techniques Pediatric and congenital heart disease, including cardiovascular surgery Cardiac development Epidemiology

(Circulation. 2006;114:1873-1882.)
© 2006 American Heart Association, Inc.

Congenital Heart Disease for the Adult Cardiologist

Patent Ductus Arteriosus

Douglas J. Schneider, MD; John W. Moore, MD, MPH

From the University of Illinois College of Medicine at Peoria and Cardiac Catheterization Laboratory, Children’s Hospital of Illinois, Peoria, Ill (D.J.S.); and University of California at San Diego and Rady’s Children’s Hospital, San Diego (J.W.M.).

Correspondence to Douglas J. Schneider, MD, Clinical Associate Professor of Pediatrics, University of Illinois College of Medicine at Peoria, Director, Cardiac Catheterization Laboratory, Children’s Hospital of Illinois, 420 NE Glen Oak Ave, Suite 304, Peoria, IL 61603. E-mail djs{at}pedcard.com

Key Words: ductus arteriosus, patent • heart defects, congenital • heart diseases

	Introduction

Top Introduction Embryology Normal Physiology Epidemiology Anatomy Pathophysiology Clinical Features Natural History and... Medical Management Definitive Therapy: Closure of... Conclusions References

 
The patent ductus arteriosus (PDA) is a vascular structure that connects the proximal descending aorta to the roof of the main pulmonary artery near the origin of the left branch pulmonary artery. This essential fetal structure normally closes spontaneously after birth. After the first few weeks of life, persistence of ductal patency is abnormal. The physiological impact and clinical significance of the PDA depend largely on its size and the underlying cardiovascular status of the patient. The PDA may be "silent" (not evident clinically but diagnosed incidentally by echocardiography done for a different reason), small, moderate, or large. Regardless of the size, complications may arise, and it is important for both pediatric and adult cardiologists to have an understanding of the pathophysiology, clinical implications, and management of PDA.

	Embryology

Top Introduction Embryology Normal Physiology Epidemiology Anatomy Pathophysiology Clinical Features Natural History and... Medical Management Definitive Therapy: Closure of... Conclusions References

 
The ductus arteriosus is a normal and essential fetal structure that becomes abnormal if it remains patent after the neonatal period. In normal cardiovascular development, the proximal portions of the sixth pair of embryonic aortic arches persist as the proximal branch pulmonary arteries, and the distal portion of the left sixth arch persists as the ductus arteriosus, connecting the left pulmonary artery with the left dorsal aorta (Figure 1). Normally, the distal right sixth aortic arch loses its connection to the dorsal aorta and degenerates. This transformation is complete by 8 weeks of fetal life.

View larger version (26K): [in this window] [in a new window]   Figure 1. Schematic of embryonic aortic arch system. The 6 pairs of embryonic aortic arches are demonstrated (left-sided arches are numbered). The portions that normally involute are indicated by broken lines. The distal left sixth embryonic arch normally persists and becomes the PDA, connecting the left pulmonary artery to the proximal descending aorta. The right distal sixth arch normally involutes, as does the eighth segment of the right dorsal aorta (*), which results in a leftward aortic arch. RCA indicates right carotid artery; LCA, left carotid artery; RSCA, right subclavian artery; and LSCA, left subclavian artery.

	Normal Physiology

Top Introduction Embryology Normal Physiology Epidemiology Anatomy Pathophysiology Clinical Features Natural History and... Medical Management Definitive Therapy: Closure of... Conclusions References

 
Fetal Circulation
Whereas 65% of the fetal cardiac output is from the right ventricle, only 5% to 10% passes through the lungs.^1,2 The preponderance of right ventricular output passes through the ductus arteriosus into the descending aorta. The fetal ductus arteriosus is thus an important structure that is essential for normal fetal development, permitting right ventricular output to be diverted away from the high-resistance pulmonary circulation. Premature constriction or closure may lead to right heart failure, resulting in fetal hydrops.³

Histology and Mechanisms of Normal Closure
Grossly, the constitution of the fetal ductus arteriosus appears to be similar to the contiguous main pulmonary artery and descending aorta; there are important histological differences, however.^4–9 Whereas the mediae of surrounding aorta and pulmonary artery are composed mainly of circumferentially arranged layers of elastic fibers, the media of the ductus arteriosus is composed of longitudinally and spirally arranged layers of smooth muscle fibers within loose, concentric layers of elastic tissue. The intima of the ductus arteriosus is thickened and irregular, with abundant mucoid material, sometimes referred to as intimal cushions.

Fetal patency of the ductus arteriosus is controlled by many factors, the most important of which are relatively low fetal oxygen tension¹⁰ and cyclooxygenase-mediated products of arachidonic acid metabolism (primarily prostaglandin [PGE₂] and prostacyclin [PGI₂]).¹¹ Locally produced and circulating PGE₂ and PGI₂ in the fetus cause vasodilation of the ductus arteriosus via interaction with ductal prostanoid receptors,¹² and circulating PGE₂ and PGI₂ levels are high in the fetus because of production by the placenta and decreased metabolism in the fetal lungs.

After birth, the abrupt increase in oxygen tension inhibits ductal smooth muscle voltage-dependent potassium channels, which results in an influx of calcium and ductal constriction.¹³ PGE₂ and PGI₂ levels fall because of metabolism in the now functioning lungs and elimination of the placental source. The medial smooth muscle fibers in the ductus contract, which results in wall thickening, lumen obliteration, and shortening of the ductus arteriosus. Functional complete closure usually occurs within 24 to 48 hours of birth in term neonates. Within the next 2 to 3 weeks, infolding of the endothelium along with subintimal disruption and proliferation result in fibrosis and a permanent seal.¹⁴ The resulting fibrous band with no lumen persists as the ligamentum arteriosum.

	Epidemiology

Top Introduction Embryology Normal Physiology Epidemiology Anatomy Pathophysiology Clinical Features Natural History and... Medical Management Definitive Therapy: Closure of... Conclusions References

 
The factors responsible for persistent patency of the ductus arteriosus beyond the first 24 to 48 hours of neonatal life are not completely understood. Prematurity clearly increases the incidence of PDA, and this is due to physiological factors related to prematurity rather than inherent abnormality of the ductus.¹⁵ In term infants, cases most often appear to occur sporadically, but there is increasing evidence that genetic factors play a role in many patients with patent ductus. In addition, other factors such as prenatal infection appear to play a role in some cases.

Incidence
The reported incidence of PDA varies because of methodological differences related to the population group studied, age of consideration, and method of detection.¹⁶ Although the ductus arteriosus usually is functionally closed within 48 hours of birth, some authorities consider the patent ductus to be abnormal only after 3 months of age.¹⁷ In children who were born at term, the incidence of PDA has been reported to be 1 in 2000 births.^18,19 This accounts for 5% to 10% of all congenital heart disease. However, if we include children with "silent" patent ductus (those discovered incidentally by echocardiography performed for another purpose), the incidence has been estimated to be as high as 1 in 500.²⁰ The female to male ratio is 2:1 in most reports.

Genetic Factors
In contrast to premature infants, in whom PDA generally is due to developmental immaturity, patent ductus in term infants likely results from a significant structural abnormality. PDA occurs with increased frequency in several genetic syndromes, including those with defined chromosomal aberrations (such as trisomy 21 and 4p– syndrome), single-gene mutations (such as Carpenter’s syndrome and Holt-Oram syndrome), and X-linked mutations (such as incontinentia pigmenti). Although most cases of PDA are seemingly sporadic, many are believed to be due to multifactorial inheritance, with the requirement of genetic predisposition and an environmental trigger that occurs at a vulnerable time.²¹ The genetic mechanism of patent ductus in some patients may be autosomal recessive inheritance with incomplete penetrance.²² In a family having 1 sibling with a PDA, there is an 3% chance of a PDA in a subsequent offspring.²¹

The precise mechanisms of how these genetic abnormalities result in persistent patency of the ductus arteriosus are not clear. Genetic studies suggest that the abnormalities in Char syndrome (an inherited disorder with PDA, facial dimorphism, and hand anomalies) result from derangement of neural crest cell derivatives.^23,24 There is also evidence of abnormal fibronectin-dependent smooth muscle cell migration as a cause of PDA. Further elucidation of these mechanisms might provide the opportunity for specific targeted genetic or biochemical therapies for PDA and might also provide insight into the development of new strategies to maintain ductal patency in ductal-dependent congenital heart disease.

Infection and Environmental Factors
Rubella infection during the first trimester of pregnancy, particularly in the first 4 weeks, is associated with a high incidence of PDA.^25,26 The histology resembles that of a very immature ductus, and there is an extensive subendothelial elastic lamina that is thought to be incompatible with anatomic sealing.²⁷ PDA has been reported to be associated with other environmental factors, such as in fetal valproate syndrome,²⁸ although the mechanism has not been determined.

	Anatomy

Top Introduction Embryology Normal Physiology Epidemiology Anatomy Pathophysiology Clinical Features Natural History and... Medical Management Definitive Therapy: Closure of... Conclusions References

 
In the normal heart with a left-sided aortic arch, the ductus arteriosus connects the left pulmonary artery near its origin to the descending aorta just distal to the left subclavian artery. The ductus arteriosus may persist in a wide variety of sizes and configurations. Usually, the aortic end of the patent ductus is larger than the pulmonary artery end, which results in a somewhat conical configuration. The size, configuration, and relationship to adjacent structures are important with respect to determining resistance to blood flow (an important determinant in the degree of shunting) and also have important implications with regard to interventional closure. Figure 2 demonstrates the wide variability in patent ductus size and configuration using the angiographic classification originally devised to help guide transcatheter closure procedures²⁹ and shows examples of each type.

View larger version (47K): [in this window] [in a new window]   Figure 2. Variations in PDA configuration illustrated with the classification of Krichenko et al.29 The configurations are sketched on the left, and examples of lateral angiograms for each type are on the right. A, Type A ("conical") ductus, with well-defined aortic ampulla and constriction near the pulmonary artery end. B, Very large type B ("window") ductus, with very short length. C, Type C ("tubular") ductus, which is without constrictions. D, Type D ("complex") ductus, which has multiple constrictions. E, Type E ("elongated") ductus, with the constriction remote from the anterior edge of the trachea.

	Pathophysiology

Top Introduction Embryology Normal Physiology Epidemiology Anatomy Pathophysiology Clinical Features Natural History and... Medical Management Definitive Therapy: Closure of... Conclusions References

 
Left-to-Right Shunting
The hemodynamic impact of PDA in an otherwise normal cardiovascular system is determined by the magnitude of shunting, which depends largely on the flow resistance of the ductus arteriosus. The length, the narrowest diameter, and the overall shape and configuration of the ductus arteriosus determine resistance. In addition, because flow in the ductus is dynamic and pulsatile, the elasticity of the ductus wall may affect the impedance to blood flow.³⁰

The magnitude of shunt flow depends not only on the ductal resistance but also on the pressure gradient between the aorta and the pulmonary artery. This pressure gradient is dynamic, with systolic and diastolic components, and depends largely on pulmonary and systemic vascular resistances and cardiac output. The impact of changes in pulmonary and systemic resistances is greater in larger ductus that have less flow resistance.

Left-to-right shunting through the ductus arteriosus results in pulmonary overcirculation and left heart volume overload. Increased pulmonary flow from the ductal shunting leads to increased pulmonary fluid volume, and in patients with moderate or large shunts, this causes decreased lung compliance, which may result in increased work of breathing. Pulmonary edema is uncommon but may occur in older patients with advanced congestive heart failure.

Increased flow returning to the left heart results in increased left atrial and left ventricular end-diastolic pressures. The left ventricle compensates by increasing stroke volume and eventually may hypertrophy to normalize wall stress. Neuroendocrine adaptations also occur, with increased sympathetic activity and circulating catecholamines that result in increased contractility and heart rate. The diastolic blood pressure in the aorta decreases owing to diastolic "runoff" through the patent ductus and, coupled with shorter diastolic time due to tachycardia, increased intramyocardial tension from left ventricular dilatation, and increased myocardial oxygen demand, may result in subendocardial ischemia.³¹

Eisenmenger’s Syndrome
With long-standing left-to-right shunting, exposure of the pulmonary artery system to high-pressure and increased flow leads to progressive morphological changes in the pulmonary vasculature. These changes, including arteriolar medial hypertrophy, intimal proliferation and fibrosis, and eventual obliteration of pulmonary arterioles and capillaries, result in a progressive increase in pulmonary vascular resistance. When pulmonary vascular resistance approaches and exceeds systemic vascular resistance, ductal shunting reverses and becomes right to left. The precise pathophysiological mechanisms for this are not completely understood, but there is evidence that microvascular injury stimulates production of growth factors and enzymes that result in intimal proliferation and medial hypertrophy.³² Endothelial dysfunction and platelet activation may also play a role in the obliteration of pulmonary arterioles.³³

	Clinical Features

Top Introduction Embryology Normal Physiology Epidemiology Anatomy Pathophysiology Clinical Features Natural History and... Medical Management Definitive Therapy: Closure of... Conclusions References

 
Medical History
The clinical history of patients with PDA varies from those who are completely asymptomatic to those with severe congestive heart failure or Eisenmenger’s syndrome. Many patients present for evaluation of an asymptomatic heart murmur. Others are detected incidentally by an echocardiogram performed for another purpose in patients with no overt clinical manifestations. Some patients may be relatively well but report exercise intolerance or have the diagnosis of reactive airways disease. Although most patients with PDA compensate well even with a moderate left-to-right shunt and remain asymptomatic during childhood, many years of chronic volume overload may lead to symptoms of congestive heart failure in adulthood. Symptoms may begin with onset of atrial fibrillation that results from chronic and gradually progressive left atrial enlargement. A previously well-tolerated PDA may become clinically significant when its effects are combined with acquired conditions such as ischemic heart disease or calcific aortic stenosis.

Physical Examination
The physical examination findings vary as much as the medical history. Patients with tiny, incidentally discovered patent ductus have no abnormal physical findings. The hallmark physical finding is a continuous murmur, located at the upper left sternal border, often referred to as a "machinery" murmur. The murmur often radiates down the left side of the sternum and into the back, and a thrill may be present. Occasionally a diastolic rumble is audible at the cardiac apex in patients with moderate or large ductal shunts. If the shunt is moderate or large, the left ventricular impulse will be prominent, and the pulse pressure will be increased. The peripheral pulses may be prominent or bounding. Except in older patients with congestive heart failure, rales are uncommon even with a large shunt.

Patients with Eisenmenger’s syndrome are cyanotic and may have differential cyanosis (cyanosis and clubbing of the toes but not the fingers because the right-to-left ductal shunting is distal to the subclavian arteries). Cyanosis may be more profound when systemic vascular resistance is decreased, such as in hot weather or after exercise. There may be no murmur during systole or diastole, because shunting may be minimal. Auscultation may reveal a high-frequency diastolic decrescendo murmur of pulmonary regurgitation and/or a holosystolic murmur from tricuspid valve regurgitation. The intensity of the pulmonic component of the second heart sound may be increased. Peripheral edema may be present late in the course of disease when right ventricular dysfunction is present.

Chest Radiograph
Depending on the amount of ductal shunting, the chest radiograph may be completely normal or it may demonstrate cardiomegaly (specifically with signs of left atrial and left ventricular enlargement) with increased pulmonary vascular markings. The main pulmonary artery is frequently enlarged, and particularly in older adults with pulmonary hypertension, calcification of the ductus may be evident.

Electrocardiogram
The ECG may demonstrate sinus tachycardia or atrial fibrillation, left ventricular hypertrophy, and left atrial enlargement in patients with moderate or large ductus shunts. In patients with smaller ductal shunts, the ECG is often completely normal. In the patient with a large ductus arteriosus and elevated pulmonary artery pressure, signs of right atrial enlargement and biventricular hypertrophy are frequently present.

Echocardiogram
The echocardiogram is the procedure of choice to confirm the diagnosis and to characterize a PDA (Figure 3). In conjunction with the clinical information, the echocardiogram is often useful in classifying the PDA as silent, small, moderate, or large. In addition to evaluating the ductus arteriosus, the echocardiogram is used to identify and evaluate other associated cardiac defects.

View larger version (53K): [in this window] [in a new window]   Figure 3. Echocardiogram study demonstrating PDA. A, Two-dimensional image of a PDA as seen in a high parasternal short-axis view. DAO indicates descending aorta; MPA, main pulmonary artery. B, Color Doppler image in a similar view shows left-to-right shunting through the ductus. C, Spectral Doppler profile of continuous left-to-right ductal flow.

M-mode echocardiography is used to measure the cardiac chamber sizes and quantitate left ventricular systolic function. In a patient with a small ductus arteriosus, chamber sizes are usually normal, although mild left atrial and/or left ventricular enlargement may be present. In a patient with a moderate or large patent ductus, the left atrium and left ventricle are enlarged. Two-dimensional imaging demonstrates the geometry of the ductus. Color Doppler is a very sensitive modality in detecting the presence of a PDA and is frequently used to estimate the degree of ductal shunting. Even an extremely tiny patent ductus can be detected by a color flow signal entering the pulmonary artery near the origin of the left pulmonary artery. In patients with high pulmonary vascular resistance and PDA, with low velocity or right-to-left flow, the ductus arteriosus may be very difficult to demonstrate with color flow Doppler, even if it is large. Findings such as septal flattening, unexplained right ventricular hypertrophy, and high-velocity pulmonary regurgitation should prompt a thorough investigation for a PDA. Contrast echocardiography may be helpful in this setting; intravenous injection of agitated saline leads to microbubbles in the descending aorta (from ductal right-to-left shunting) but not in the ascending aorta.

A complete pulmonary artery pressure curve can be generated from the spectral Doppler signal of ductal flow.³⁴ The right ventricular pressure can be estimated from the peak velocity of the tricuspid regurgitation jet, if present. The Doppler velocity of the pulmonary regurgitation flow, if present, can be used to estimate the pulmonary artery diastolic pressure. With the outflow tract cross-sectional areas and Doppler-derived mean flow velocities, the degree of left-to-right shunt can be calculated.

Magnetic Resonance Imaging and Computed Tomography
In the adult with PDA, computed tomography can assess the degree of calcification,³⁵ which may be important if surgical therapy is considered. Magnetic resonance imaging and computed tomography may be useful in defining the anatomy in patients with unusual PDA geometry and in patients with associated abnormalities of the aortic arch.³⁶ One example is the patient with ductus arteriosus aneurysm, which may present as a chest mass.^37,38 Other examples include PDA associated with vascular ring, with right aortic arch, and with cervical arch.

Cardiac Catheterization
Therapeutic catheterization is currently the treatment of choice at most centers for most children and adults with patent ductus. Complete diagnostic assessment of hemodynamics before transcatheter closure is particularly important in adults with patent ductus, in whom it is imperative to fully evaluate the pulmonary vascular resistance and degree of shunting before intervention. In patients with elevated pulmonary artery pressure, assessment of pulmonary vascular resistance and its response to vasodilating agents such as oxygen, nifedipine, prostacyclin, sildenafil, and nitric oxide may be helpful in determining advisability of ductus closure. Assessment of hemodynamics during temporary test occlusion with a balloon catheter may also provide important information regarding advisability of closure.

Angiography defines the anatomy of the ductus arteriosus. Detailed assessment of the ductal anatomy is essential before transcatheter closure so that the proper device and device size can be chosen for the intervention. Important features include the minimum diameter, the largest diameter (usually at the aortic ampulla), the length, and the relationship of the ductus to the anterior border of the tracheal shadow, which helps guide device positioning.

	Natural History and Complications

Top Introduction Embryology Normal Physiology Epidemiology Anatomy Pathophysiology Clinical Features Natural History and... Medical Management Definitive Therapy: Closure of... Conclusions References

 
The natural history of PDA depends largely on the size and magnitude of the shunt and the status of the pulmonary vasculature. Many patients with small ductus arteriosus never have signs of significant hemodynamic impairment and, other than the risk of endarteritis, have a normal prognosis. Those patients with significant left heart volume overload, however, are at risk of congestive heart failure or irreversible pulmonary vascular disease, even if asymptomatic or minimally symptomatic during childhood.

Congestive Heart Failure
Children and adults with moderate to large patent ductus frequently develop symptoms of congestive heart failure due to pulmonary overcirculation and left heart volume overload. If the ductus is large and offers minimal resistance to flow (nonrestrictive), the degree of shunting depends on the status of the pulmonary vascular resistance. In many children with moderate or large patent ductus, pulmonary vascular resistance remains modestly elevated, which limits the shunting sufficiently to lessen the physiological impact and permit survival and growth. Although patients with small to moderate ductus often remain asymptomatic during infancy and childhood, and some may never develop symptoms, those with significant chronic volume overload of the left heart may develop congestive heart failure in adulthood, starting in the third decade.³⁹ In the adult, heart failure is frequently associated with atrial flutter or fibrillation.⁴⁰

Hypertensive Pulmonary Vascular Disease
Patients with large nonrestrictive or minimally restrictive patent ductus are likely to eventually develop irreversible pulmonary vascular disease.⁴¹ Some cases appear to be secondary to long-standing pressure and volume overload in the pulmonary circulation, although many cases appear to be related to coincident primary pulmonary vascular disease rather than occurring as a result of the ductus.⁴² Some infants and children with a large patent ductus do not experience the normal postnatal fall in pulmonary vascular resistance, and even after closure of the ductus, pulmonary vascular disease may progress and eventually prove fatal.^42,43

Endarteritis
The incidence of infective arteritis associated with PDA has decreased dramatically since the early natural history studies before the era of routine surgical closure and use of antibiotics, when the incidence of infective arteritis was reported to be 1% per year.^39,44–47 The reasons for this decline are probably many and include the improved availability of health care, including dental care; widespread use of antibiotics, including use for infective endocarditis prophylaxis; and importantly, the fact that routine closure of PDA over the past few decades has markedly decreased the substrate. In countries with limited health resources and access to health care, infective endarteritis associated with ductus arteriosus remains a significant health issue.⁴⁸ Vegetations usually occur on the pulmonary artery end of the ductus, and embolic events are usually of the lung rather than the systemic circulation.

Aneurysm of Ductus Arteriosus
Aneurysm of the ductus arteriosus is an entity with a reported incidence as high as 8%.⁴⁹ The true incidence is unclear because the definition of ductus arteriosus aneurysm is not precise and because many incidentally discovered ductus arteriosus aneurysms detected by fetal or neonatal echocardiography resolve spontaneously with ductal closure and thrombosis, without clinically apparent sequelae.⁵⁰ Ductal aneurysm most commonly presents in infancy^49–51 but has also been reported in adults⁵² and may develop after infective endarteritis, surgical closure, or transcatheter coil occlusion.^53–55 In approximately one fourth of patients, an underlying disorder such as trisomy 21, trisomy 13, Smith-Lemli-Opitz syndrome, type IV Ehlers-Danlos syndrome, or Marfan’s syndrome is present.⁵¹

Rarely, the ductus arteriosus aneurysm may present with symptoms of a thoracic mass, including hoarseness due to left vocal chord paralysis from recurrent left laryngeal nerve impingement⁵⁶ and left bronchial obstruction.⁵⁷ Although many have a benign course, surgical resection is indicated if there is functional compromise of adjacent structures, persistent patency of the ductus, thrombus that extends into adjacent vessels, evidence of thromboembolic events, or underlying connective tissue disease.⁵¹ The role of percutaneous occlusion with aneurysm obliteration has not been established for ductus arteriosus aneurysm, but one potentially promising technique is placement of a covered stent in the aorta to simultaneously exclude the aneurysm and occlude the ductus arteriosus.⁵⁸

Other Complications
PDA, particularly in association with pulmonary hypertension, may lead to recurrent laryngeal nerve paralysis even without aneurysm, due to impingement of the nerve as it courses through the triangle formed by the aortic arch, enlarged pulmonary artery, and ductus arteriosus.⁵⁹ Dissection and/or spontaneous rupture of an aneurysmally dilated pulmonary artery due to PDA with pulmonary hypertension may occur.^60–62 In addition, acute aortic dissection may also occur.⁶³ These complications are rare.

	Medical Management

Top Introduction Embryology Normal Physiology Epidemiology Anatomy Pathophysiology Clinical Features Natural History and... Medical Management Definitive Therapy: Closure of... Conclusions References

 
Symptomatic patients with PDA usually improve with a medical regimen of diuretics and digoxin. Afterload reduction, such as with angiotensin-converting enzyme inhibition, may also affect clinical improvement, although definitive studies in this setting are not available. Antidysrhythmia medications may be useful in patients with atrial fibrillation or flutter, and although some patients may be successfully cardioverted and maintained in sinus rhythm after closure of the ductus, adults with atrial fibrillation may require therapy indefinitely, including anticoagulation. Observance of infective endocarditis prophylaxis precautions is recommended for all patients with PDA, including those with silent PDA, until 6 months after closure. Medical therapy for congestive heart failure due to PDA may be short-term, until definitive surgical or transcatheter closure is performed, but may also be required long-term in patients with cardiomegaly and persistent symptoms.

Patients with PDA and pulmonary vascular disease who are considered unacceptable candidates for definitive closure may be managed with pulmonary vasodilating agents such as chronic oxygen, PGI₂, calcium channel blockers, endothelin antagonists, and phosphodiesterase type V inhibitors. One strategy in such patients is to accomplish partial closure of the ductus by surgery or transcatheter techniques, to make it "restrictive" but not completely closed, followed by long-term therapy with pulmonary vasodilating agents. If in follow-up, the pulmonary vascular resistance decreases, then complete closure may be considered. Systematic study of the benefits of pulmonary vasodilating agents in the setting of PDA and high pulmonary vascular resistance are not available, however, and such treatment strategies are unproved and results anecdotal at the present time.

	Definitive Therapy: Closure of PDA

Top Introduction Embryology Normal Physiology Epidemiology Anatomy Pathophysiology Clinical Features Natural History and... Medical Management Definitive Therapy: Closure of... Conclusions References

 
Historical Perspective
Techniques for closure of PDA have evolved since the first report of surgical ligation by Gross and Hubbard in 1939.⁶⁴ Transcatheter methods, to avoid thoracotomy, were pioneered by Portsmann et al,⁶⁵ who reported use of a conical Ivalon plug in 1967, and by Rashkind and Cuaso,⁶⁶ who reported initial results of an umbrella-type device in 1979. These devices were rather large and cumbersome to use, requiring large introducer sheaths and frequently leaving residual shunting. After Cambier et al⁶⁷ in 1992 reported the use of Gianturco coils for transcatheter closure of PDA, transcatheter coil occlusion quickly became a widely used technique for closure of the small to moderate patent ductus. Subsequently, newer devices and techniques have been developed such that moderate and large patent ductus are usually amenable to occlusion by transcatheter techniques. In addition, the development of less invasive surgical techniques has paralleled the development of transcatheter techniques.

Indications for Closure of PDA
Ductus closure is clearly indicated for any child or adult who is symptomatic from significant left-to-right shunting through the PDA. In asymptomatic patients with significant left-to-right shunting that results in left heart enlargement, closure is indicated to minimize the risk of complications in the future.⁶⁸ In adults with PDA, reported outcomes after PDA closure have been very good, including for those with modest elevation in pulmonary vascular resistance and even some with Eisenmenger’s syndrome.⁶⁹ Elimination of the shunt reduces pulmonary blood flow, and therefore pulmonary artery pressure, even if the pulmonary vascular resistance remains elevated.⁷⁰

In patients with pulmonary vascular resistance >8 U/m², lung biopsy has been recommended to determine candidacy for closure.⁷¹ Such patients may be hemodynamically worse after ductal closure because of loss of the avenue for right-to-left shunting, which leads to suprasystemic pulmonary artery pressure, low cardiac output, and right ventricular failure. Unfortunately, lung biopsy may not be sufficiently predictive to justify the risk. Pulmonary vascular disease characterized by histological changes consistent with severe, irreversible pulmonary vascular disease may completely resolve after closure of the PDA.⁷² Reactivity of the pulmonary vascular bed to pulmonary vasodilating agents and/or significant reduction of pulmonary artery pressure and resistance during test occlusion may offer reassurance with regard to reversibility, but the absence of such evidence does not exclude the possibility of reversibility in the long term.

The indications for closure of patent ductus with small shunts, including those that are tiny and incidentally discovered ("silent"), are less certain, particularly in older adults. Endarteritis of clinically silent PDA has been reported.^73,74 Although the incidence of ductus arteriosus endarteritis has decreased dramatically over the past several decades, the risk has not disappeared completely. Because closure methods are effective and safe and are associated with minimal morbidity, a strategy advocating routine closure of any PDA in children and young adults appears most reasonable.

Transcatheter Closure
Transcatheter occlusion has become the treatment of choice for most patent ductus in children and adults. In cases of calcified ductus arteriosus with increased pulmonary vascular resistance, transcatheter closure offers considerable advantages over surgical closure, which frequently involves cardiopulmonary bypass with an anterior approach through a median sternotomy.

The basic technique is to advance a catheter or delivery sheath across the ductus arteriosus from either the pulmonary artery or the aorta and position a closure device in the ductus to occlude it. Since the initial experience with standard, nondetachable Gianturco coils, which occasionally migrated or assumed unacceptable positions, several techniques were developed to stabilize the coils during delivery.^75–77 In addition, detachable coils are now readily available, which allow the assessment of adequate positioning before release. Figure 4 demonstrates an example of ductus occlusion with a standard Gianturco coil.

View larger version (131K): [in this window] [in a new window]   Figure 4. Example of Gianturco coil occlusion of PDA. A, Views of a Gianturco coil in its stretched out configuration (top) and in its natural coiled configuration (bottom). Note the attached Dacron fibers, which promote thrombosis, along its length. B through D, Lateral angiograms demonstrating closure of a PDA with a single 0.038-in diameter Gianturco coil.

In contrast to Gianturco coils, which were designed for occlusion of vascular structures other than the patent ductus, the Nit-Occlud coil occlusion⁷⁸ system was specifically designed for closure of the PDA. The coil has a biconical shape that is more suitable to the conical shape of most patent ductus than the cylindrical Gianturco coils. Figure 5 demonstrates closure of a PDA with a Nit-Occlud coil. For closure of moderate and large patent ductus, the Amplatzer duct occluder⁷⁹ is frequently used (Figure 6). This device is made of nitinol wire woven into a mesh in the configuration of a mushroom-shaped plug, and it has a detachable cable, which allows easy repositioning or retrieval if necessary. For some patients with larger type B (short) ductus, the Amplatzer septal occluder device, a Dacron fiber–filled nitinol mesh with 2 disks connected by a short waist, may be effective.

View larger version (123K): [in this window] [in a new window]   Figure 5. Example of PDA closure with a Nit-Occlud PDA occlusion device. A, Image of a Nit-Occlud coil with its biconical configuration. Note the reversed winding on the proximal end. B through D, Lateral angiograms demonstrating closure of a PDA with a single Nit-Occlud coil.

View larger version (122K): [in this window] [in a new window]   Figure 6. Example of PDA occlusion with an Amplatzer duct occluder device. A, Image of an Amplatzer duct occluder device. B through D, Lateral angiograms demonstrating closure of a PDA with an Amplatzer duct occluder device.

In addition to the devices described above, newer devices and modifications are in the process of being developed and tested. The Amplatzer duct occluder has been modified such that the retention skirt has an angle and concavity that allows it to fit better at the aortic end, and this device is currently under investigation.⁸⁰ Other devices that are currently in use and are investigational are the modified folding-plug buttoned device⁸¹ and the wireless patch developed by Sideris and associates.⁸² Given the numerous variations of PDA configuration and size, it is apparent that any individual device will not be optimal for closure of all patent ductus. The availability of a variety of devices and techniques enhances the capability to close the vast majority of patent ductus with catheter-based techniques.

Results of transcatheter occlusion of PDA have been excellent. Complete closure rates at follow-up generally exceed 90% to 95% in most studies.⁸² As a result of device modifications, evolution of new techniques, and increased operator skill, success rates for complete closure have improved significantly over time. Even when a small residual shunt is detected at follow-up, complete occlusion can usually be achieved by delivery of a single small additional coil.

Serious complications of transcatheter closure of the patent ductus are rare. The most common complication is device embolization, which was relatively common early in the experience with coils. Embolized coils are usually retrieved, but even in cases in which they cannot be retrieved, adverse consequences are rare. Other potentially important complications are flow disturbance in the proximal left pulmonary artery or descending aorta from a protruding device, hemolysis from high-velocity residual shunting, femoral artery or vein thrombosis related to vascular access, and infection.

Surgical Therapy
Although generally associated with greater pain and morbidity than transcatheter methods, surgical ligation and surgical division are safe and effective procedures that historically have set a high standard by which transcatheter techniques have been judged. Surgical ligation or division of the PDA remains the treatment of choice for the rare very large ductus. Rarely, a large, window-type PDA may have insufficient length to permit ligation, and the appropriate surgical procedure is patch closure on cardiopulmonary bypass.⁸³ Complete closure rates of surgical ligation (often accompanied by division of the ductus) in published reports range from 94% to 100%, with 0% to 2% mortality.^84–86 Important complications include bleeding, pneumothorax, infection, and rarely, ligation of the left pulmonary artery or aorta. Surgical morbidity, cost, and hospital length of stay have been decreased with use of transaxillary muscle-sparing thoracotomy^87,88 and by the technique of video-assisted thoracoscopic ligation of the PDA.⁸⁹

	Conclusions

Top Introduction Embryology Normal Physiology Epidemiology Anatomy Pathophysiology Clinical Features Natural History and... Medical Management Definitive Therapy: Closure of... Conclusions References

 
PDA is a cardiovascular disorder found in patients of all ages and sizes, from tiny premature infants to older adults. The clinical implications vary depending on the anatomy of the ductus arteriosus and the underlying cardiovascular status of the patient. Before the advent of surgical treatment for PDA in 1939, management for this disorder was palliative. Over the past 3 decades, transcatheter techniques have replaced surgical therapy in most patients with PDA. Concurrently, advances in diagnostic echocardiography and the widespread availability of echocardiography have resulted in improved detection and characterization of PDA in patients of all ages. Complications of PDA can be avoided or ameliorated by appropriate diagnosis and management.

	Acknowledgments

 
Disclosures

Dr Moore serves as a proctor for AGA Medical Corporation, maker of the Amplatzer PDA occluder device, and as a proctor and consultant for PFM Medical, maker of the Nit-Occlud PDA occlusion device. Dr Schneider reports no conflicts.

	References

Top Introduction Embryology Normal Physiology Epidemiology Anatomy Pathophysiology Clinical Features Natural History and... Medical Management Definitive Therapy: Closure of... Conclusions References

 
1. Heymann MA, Creasy RK, Rudolph AM. Quantitation of blood flow patterns in the foetal lamb in utero. In: Proceedings of the Sir Joseph Barcroft Centenary Symposium: Foetal and Neonatal Physiology. Cambridge, UK: Cambridge University Press; 1973: 129–135.

2. Reed KL, Meijboom EJ, Sahn DJ, Scagnelli SA, Valdes-Cruz LM, Shenker L. Cardiac Doppler flow velocities in human fetuses. Circulation. 1986; 73: 41–46.[Abstract/Free Full Text]

3. Leal SD, Cavalle-Garrido T, Ryan G, Farine D, Helibut M, Smallhorn JF. Isolated ductal closure in utero diagnosed by fetal echocardiography. Am J Perinatol. 1997; 14: 205–210.[Medline] [Order article via Infotrieve]

4. Record FG, McKeown T. Observations relating to the aetiology of patent ductus arteriosus. Br Heart J. 1953; 15: 376–386.[Free Full Text]

5. Fay FS, Cooke PH. Guinea pig ductus arteriosus, 2: irreversible closure after birth. Am J Physiol. 1972; 222: 841–849.[Free Full Text]

6. Gittenberger-De Groot AC, Van Ertbruggen I, Moulaert AJ, Harinck E. The ductus arteriosus in the preterm infant: histologic and clinical observations. J Pediatr. 1980; 96: 88–93.[CrossRef][Medline] [Order article via Infotrieve]

7. Graper L. Die anatomischen Varanderungen kurx nach der Gebert III. Ductus botalli. Z Anat Entwicklungsgesch. 1927; 61: 312–329.

8. Desligneres S, Larroch JC. Ductus arteriosus, 1: anatomical and histologic study of its development during the second half of gestation and its closure after birth; 2: histological study of a few cases of patent ductus arteriosus in infancy. Biol Neonate. 1970; 16: 278–296.[Medline] [Order article via Infotrieve]

9. Silver MM. The morphology of the human newborn ductus arteriosus: a reappraisal of its structure and closure with special reference to prostaglandin E1 therapy. Hum Pathol. 1981; 12: 1123–1136.[Medline] [Order article via Infotrieve]

10. Heymann MA, Rudolf AM. Control of the ductus arteriosus. Physiol Rev. 1975; 55: 62–78.[Abstract/Free Full Text]

11. Coceani F, Olley PM. The response of the ductus arteriosus to prostaglandins. Can J Physiol Pharmacol. 1973; 51: 220–225.[Medline] [Order article via Infotrieve]

12. Michelakis E, Rebeyka I, Bateson J, Olley P, Puttagunta L, Archer S. Voltage-gated potassium channels in human ductus arteriosus. Lancet. 2000; 356: 134–137.[CrossRef][Medline] [Order article via Infotrieve]

13. Leonhardt A, Glaser A, Wegmann M, Schranz D, Seyberth H, Nusing R. Expression of prostanoid receptors in human ductus arteriosus. Br J Pharmacol. 2003; 138: 655–659.[CrossRef][Medline] [Order article via Infotrieve]

14. Fay FS, Kooke PH. Guinea pig ductus arteriosus, II: irreversible closure after birth. Am J Physiol. 1972; 222: 841–849.[Free Full Text]

15. Kitterman JA, Edmunds LH Jr, Gregory GA, Heyman MA, Tooley WH, Rudolph AM. Patent ductus arteriosus in premature infants: incidence, relation to pulmonary disease and management. N Engl J Med. 1972; 287: 473–477.[Medline] [Order article via Infotrieve]

16. Hoffman JIE, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002; 39: 1890–1900.[Abstract/Free Full Text]

17. Cassels DE. The Ductus Arteriosus. Springfield, Ill: Charles C. Thomas; 1973.

18. Carlgren LE. The incidence of congenital heart disease in children born in Gothenburg 1941–1950. Br Heart J. 1959; 21: 40–50.[Free Full Text]

19. Mitchell SC, Korones SB, Berendes HW. Congenital heart disease in 56,109 births: incidence and natural history. Circulation. 1971; 43: 323–332.[Abstract/Free Full Text]

20. Lloyd TR, Beekman RH III. Clinically silent patent ductus arteriosus. Am Heart J. 1994; 127: 1664–1665.Letter.[Medline] [Order article via Infotrieve]

21. Nora JJ. Multifactorial inheritance hypothesis for the etiology of congenital heart diseases: the genetic-environmental interaction. Circulation. 1968; 38: 604–617.[Abstract/Free Full Text]

22. Mani A, Meraji S, Houshyar R, Radhakrishnan J, Mani A, Ahanger M, Rezaie TM, Taghabinejad MA, Broumand B, Zhao H, Nelson-Williams C, Lifton RP. Finding genetic contributions to sporadic disease: a recessive locus at 12q24 commonly contributes to patent ductus arteriosus. Proc Nat Acad Sci U S A. 2002; 99: 15054–15059.[Abstract/Free Full Text]

23. Satoda M, Pierpont ME, Diaz GA, Bornemeier RA, Gelb BD. Char syndrome, an inherited disorder with patent ductus arteriosus, maps to chromosome 6p12-p21. Circulation. 1999; 99: 3036–3042.[Abstract/Free Full Text]

24. Satoda M, Zhao F, Diaz GA, Burn J, Goodship J, Davidson HR, Pierpont ME, Gelb BD. Mutations in TFAP2B cause Char syndrome, a familial form of patent ductus arteriosus. Nat Genet. 2000; 25: 42–46.[CrossRef][Medline] [Order article via Infotrieve]

25. Gibson S, Lewis K. Congenital heart disease following maternal rubella during pregnancy. Am J Dis Child. 1952; 83: 117–119.

26. Swan C, Tostevin AL, Black GHB. Final observations on congenital defects in infants following infectious disease during pregnancy with special reference to rubella. Med J Aust. 1946; 2: 889–908.

27. Gittenberger-de Groot AC, Moulaert AJ, Hitchcock JF. Histology of the persistent ductus arteriosus in cases of congenital rubella. Circulation. 1980; 62: 183–186.[Abstract/Free Full Text]

28. Anoop P, Sasidharan CK. Patent ductus arteriosus in fetal valproate syndrome. Indian J Pediatr. 2003; 70: 681–682.[Medline] [Order article via Infotrieve]

29. Krichenko A, Benson LN, Burrows P, Moes CA, McLaughlin P, Freedon RM. Angiographic classification of the isolated, persistently patent ductus arteriosus and implications for percutaneous catheter occlusion. Am J Cardiol. 1989; 63: 877–879.[CrossRef][Medline] [Order article via Infotrieve]

30. Tomita H, Fuse S, Hatakeyama K, Chiba S. Epinephrine-induced constriction of the persistent ductus arteriosus and its relation to distensibility. Jpn Circ J. 1998; 62: 913–914.[CrossRef][Medline] [Order article via Infotrieve]

31. Hoffman JIE, Buckberg GD. Regional myocardial ischemia: causes, prediction, and prevention. Vasc Surg. 1974; 8: 115–131.[Medline] [Order article via Infotrieve]

32. Perkett EA, Lyons RM, Moses HL, Brigham KL, Meyrick B. Transforming growth factor-beta activity in sheep lung lymph during the development of pulmonary hypertension. J Clin Invest. 1990; 86: 1459–1464.[Medline] [Order article via Infotrieve]

33. Celermajer DS, Cullen S, Deanfield JE. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics Circulation. 1993; 87: 440–446.[Abstract/Free Full Text]

34. Becker TE, Ensing GJ, Darragh RK, Caldwell RL. Doppler derivation of complete pulmonary artery pressure curves in patent ductus arteriosus. Am J Cardiol. 1996; 78: 1066–1069.[CrossRef][Medline] [Order article via Infotrieve]

35. Morgan-Jughes GJ, Marshall AJ, Roobottome C. Morphologic assessment of patent ductus arteriosus in adults using retrospectively ECG-gated multidetector CT. Am J Roentgenol. 2003; 181: 749–754.[Abstract/Free Full Text]

36. Brenner LD, Caputo GR, Mostbeck G, Steiman D, Dulce M, Cheitlin MD, O’Sullivan M, Higgins CB. Quantification of left to right atrial shunts with velocity-encoded cine nuclear magnetic resonance imaging. J Am Coll Cardiol. 1992; 20: 1246–1250.[Abstract]

37. Kussman GD, Geva T, McGowan FX. Cardiovascular causes of airway compression. Pediatr Anaesth. 2004; 14: 60–74.[CrossRef][Medline] [Order article via Infotrieve]

38. Taneja K, Gulati M, Jain M, Saxena A, Das B, Rajani M. Ductal arteriosus aneurysm in the adult: role of computed tomography in diagnosis. Clin Radiol. 1997; 52: 231–234.[CrossRef][Medline] [Order article via Infotrieve]

39. Campbell M. Natural history of patent ductus arteriosus. Br Heart J. 1968; 30: 4–13.[Free Full Text]

40. Marquis RM, Miller HDC, McCormack RJM, et al. Persistence of ductus arteriosus with left to right shunt in the older patient. Br Heart J. 1982; 48: 469–484.[Abstract/Free Full Text]

41. Espino-Vela J, Cardenas N, Cruz R. Patent ductus arteriosus with special reference to patients with pulmonary hypertension. Circulation. 1968; 38 (suppl V): V45–V60.

42. Bessinger FB Jr, Blieden LC, Edwards JE. Hypertensive pulmonary vascular disease associated with patent ductus arteriosus: primary or secondary? Circulation. 1975; 52: 157–161.[Abstract/Free Full Text]

43. Yamaki S, Ishidoya T, Osuga T, Arai S. Progressive pulmonary vascular disease after surgery in a case of patent ductus arteriosus with pulmonary hypertension. Tohoku J Exp Med. 1983; 140: 279–288.[Medline] [Order article via Infotrieve]

44. Keys A, Shapiro MJ. Patency of the ductus arteriosus in adults. Am Heart J. 1943; 25: 158–186.[CrossRef]

45. Zuberbuhler JR, Neches WH, Park SC. Infectious endocarditis: experience spanning three decades. Cardiol Young. 1994; 4: 244–251.

46. Thilen U, Astrom-Olsson K. Does the risk of infective endocarditis justify routine patent ductus arteriosus closure? Eur Heart J. 1997; 18: 503–506.[Abstract/Free Full Text]

47. Johnson DH, Rosenthal A, Nadas AS. A forty year review of bacterial endocarditis in infancy and childhood. Circulation. 1975; 51: 581–588.[Abstract/Free Full Text]

48. Sadiq, Latif F, ur-Rehman A. Analysis of infective endarteritis in patent ductus arteriosus. Am J Cardiol. 2004; 93: 513–515.[CrossRef][Medline] [Order article via Infotrieve]

49. Jan S-L, Whang B, Fu J-W, Chi C-S. Isolated neonatal ductus arteriosus aneurysm. J Am Coll Cardiol. 2002; 39: 342–348.[Abstract/Free Full Text]

50. Rutishauser M, Ronen G, Wyler F. Aneurysm of the nonpatent ductus arteriosus in the newborn. Acta Pediatr Scand. 1977; 66: 649–651.[Medline] [Order article via Infotrieve]

51. Dyamenahalli U, Smallhorn JF, Geva T, Fouron JC, Cairns P, Jutras L, Hughes V, Rabinovich M, Mason CA, Hornberger LK. Isolated ductus arteriosus aneurysm in the fetus and infant: a multi-institutional experience. J Am Coll Cardiol. 2000; 36: 262–269.[Abstract/Free Full Text]

52. Cruickshank B, Marquis RM. Spontaneous aneurysm of the ductus arteriosus. Am J Med. 1958; 25: 140–149.[CrossRef][Medline] [Order article via Infotrieve]

53. Kerwin AJ, Jaffe FA. Post-operative aneurysm of the ductus arteriosus with fatal rupture of a mycotic aneurysm of a branch of the pulmonary artery. Am J Cardiol. 1959; 3: 397–403.[CrossRef][Medline] [Order article via Infotrieve]

54. Ross RS, Feder FP, Spencer FC. Aneurysm of the previously ligated patent ductus arteriosus. Circulation. 1961; 23: 350–357.[Abstract/Free Full Text]

55. Marasini M, Rimini A, Zannini L, Pongiglione G. Giant aneurysm following coil occlusion of patent ductus arteriosus. Cathet Cardiovasc Intervent. 2000; 50: 186–189.[CrossRef][Medline] [Order article via Infotrieve]

56. Berger M, Ferguson C, Hendry J. Paralysis of the left diaphragm, left vocal cord, and aneurysm of the ductus arteriosus in a 7-day-old infant. J Paediatr. 1960; 56: 800–802.[CrossRef][Medline] [Order article via Infotrieve]

57. Roughneen PT, Parikh P, Stark J. Bronchial obstruction secondary to aneurysm of a persistent ductus arteriosus. Eur J Cardiothorac Surg. 1996; 10: 146–147.[Abstract]

58. Roques F, Hennequin JL, Sanchez B, Ridarch A, Rousseau H. Aortic stent-graft for patent ductus arteriosus in adults: the aortic exclusion technique. Ann Thorac Surg. 2001; 71: 1708–1709.[Abstract/Free Full Text]

59. Nakahira M, Nakatani H, Takeda T. Left vocal cord paralysis associated with long-standing patent ductus arteriosus. Am J of Neuroradiol. 2001; 22: 759–761.[Abstract/Free Full Text]

60. Green JN, Rollason TP. Pulmonary artery rupture in pregnancy complicating patent ductus arteriosus. Br Heart J. 1992; 68: 616–618.[Abstract/Free Full Text]

61. Coard KC, Martin MP. Ruptured saccular pulmonary artery aneurysm associated with persistent ductus arteriosus. Arch Pathol Lab Med. 1992; 16: 159–161.

62. Sardesai SH, Marshall RJ, Farrow R, Mourant AJ. Dissecting aneurysm of the pulmonary artery in a case of unoperated patent ductus arteriosus. Eur Heart J. 1990; 11: 670–673.[Abstract/Free Full Text]

63. Cusick DA, Frederikwen JW, Mehlman DJ. Acute aortic dissection: association with patent ductus arteriosus. Am J Card Imaging. 1996; 10: 200–203.[Medline] [Order article via Infotrieve]

64. Gross RE, Hubbard JP. Surgical ligation of a patent ductus arteriosus: a report of first successful case. JAMA. 1939; 112: 729–731.[Abstract/Free Full Text]

65. Portsmann W, Wierny L, Warnke H. Closure of persistent ductus arteriosus without thoracotomy. Ger Med Monthly. 1967; 12: 259–261.

66. Rashkind WJ, Cuaso CC. Transcatheter closure of a patent ductus arteriosus: successful use in a 3.5-kg infant. Pediatr Cardiol. 1979; 1: 3–7.[Medline] [Order article via Infotrieve]

67. Cambier PA, Kirby WC, Wortham DC, Moore JW. Percutaneous closure of the small (<2.5 mm) patent ductus arteriosus using coil embolization. Am J Cardiol. 1992; 69: 815–816.[CrossRef][Medline] [Order article via Infotrieve]

68. Fisher RG, Moodie DS, Sterba R, Gill CC. Patent ductus arteriosus in adults—long term follow-up: nonsurgical vs surgical treatment. J Am Coll Cardiol. 1986; 8: 280–284.[Abstract]

69. Pas D, Missauld L, Hollanders G, Suys B, DeWolf D. Persistent ductus arteriosus in the adult: clinical features and experience with percutaneous closure. Acta Cardiol. 2002; 57: 275–278.[CrossRef][Medline] [Order article via Infotrieve]

70. Shyamkrishnan KG, Singh M, Tharakan JM, Dal A. A ten-year post-surgical assessment of pulmonary hypertension in adults with patent ductus arteriosus. Indian Heart J. 1996; 48: 249–251.[Medline] [Order article via Infotrieve]

71. Yamaki S, Morhi H, Haneda H, Endo M, Akimoto H. Indications for surgery based on lung biopsy in cases of ventricular septal defect and patent ductus arteriosus with severe pulmonary hypertension. Chest. 1989; 96: 31–39.[Medline] [Order article via Infotrieve]

72. Epting CL, Wolfe RR, Abman SH, Deutsch GH, Ivy D. Reversal of pulmonary hypertension associated with plexiform lesions in congenital heart disease: a case report. Pediatr Cardio. 2002; 23: 182–185.

73. Balzer DT, Spray TL, McMullin DO, Cottingham W, Canter CE. Endarteritis associated with a clinically silent patent arterial ductus arteriosus. Am Heart J. 1993; 125: 1192–1193.[CrossRef][Medline] [Order article via Infotrieve]

74. Parthenakis FI, Kanakaraki MK, Vardas PE. Silent patent ductus arteriosus endarteritis. Heart. 2000; 84: 619.[Free Full Text]

75. Berdjis F, Moore JW. Balloon occlusion delivery technique of closure of patent arteriosus. Am Heart J. 1997; 133: 601–604.[CrossRef][Medline] [Order article via Infotrieve]

76. Ing FF, Sommer RJ. The snare-assisted technique for transcatheter coil occlusion of moderate to large patent ductus arteriosus: immediate and intermediate results. J Am Coll Cardiol. 1999; 33: 1710–1718.[Abstract/Free Full Text]

77. Hays MD, Hoyer MH, Glasow PF. New forceps delivery technique for coil occlusion of patent ductus arteriosus. Am J Cardiol. 1996; 77: 209–211.[CrossRef][Medline] [Order article via Infotrieve]

78. Moore JW, Schneider DJ, DiMeglio D. The Duct-Occlud device: design, clinical results, and future directions. J Intervent Cardiol. 2001; 14: 231–238.[Medline] [Order article via Infotrieve]

79. Pass RH, Hijazi Z, Hsu DT, Lewis V, Hellenbrand WE. Multicenter USA Amplatzer patent ductus arteriosus occlusion device trial: initial and one-year results. J Am Coll Cardiol. 2004; 44: 513–519.[Abstract/Free Full Text]

80. Masura J, Gavora P, Podnar T. Transcatheter occlusion of patent ductus arteriosus using a new angled Amplatzer duct occluder: initial clinical experience. Cathet Cardiovasc Interv. 2003; 58: 261–217.[CrossRef][Medline] [Order article via Infotrieve]

81. Sideris EB, Rao PS. Sideris’ buttoned device for transcatheter closure of patent ductus arteriosus. J Interv Cardiol. 2001; 14: 239–246.[Medline] [Order article via Infotrieve]

82. Rao, PS. Summary and comparison of patent ductus arteriosus closure methods. In: Rao PS, Kern MJ, eds. Catheter Based Devices for the Treatment of Non-Coronary Cardiovascular Disease in Adults and Children. Philadelphia, Pa: Lippincott Williams & Wilkins; 2003: 219–228.

83. Grunenfelder J, Bartram U, Van Praagh R, Bove KE, Bailey WW, Meyer RA, Koenig PR, Perez AR, Schwartz DC. The large window ductus: a surgical trap. Ann Thorac Surg. 1998; 65: 1790–1791.[Abstract/Free Full Text]

84. Mavroudis C, Backer CL, Gevitz M. Forty-six years of patent ductus arteriosus division at Children’s Memorial Hospital of Chicago: standards for comparison. Ann Surg. 1994; 220: 402–410.[Medline] [Order article via Infotrieve]

85. Ghani SA, Hashim R. Surgical management of patent ductus arteriosus: a review of 413 cases. J R Coll Surg Edinb. 1989; 34: 33–36.[Medline] [Order article via Infotrieve]

86. Galal O, Nehgme R, Al-Fadley A, deMoor M, Abbag FI, Al-Oufi SH, Williams E, Fawzy ME, al-Halees Z. The role of surgical ligation of patent ductus arteriosus in the era of the Rashkind device. Ann Thorac Surg. 1997; 63: 434–437.[Abstract/Free Full Text]

87. Cetta F, Deleon SY, Roughneen PT, Graham LC, Lichtenberg RC, Bell TJ, Vitullo Da, Fisher EA. Cost-effectiveness of transaxillary muscle-sparing same-day operative closure of patent ductus arteriosus. Am J Cardiol. 1997; 79: 1281–1282.[CrossRef][Medline] [Order article via Infotrieve]

88. Hawkins JA, Minich LL, Tani LY, Sturtivant JE, Orsmond GS, McGough EC. Cost and efficacy of surgical ligation versus transcatheter coil occlusion of patent ductus arteriosus. J Thorac Cardiovasc Surg. 1996; 112: 1634–1639.[Abstract/Free Full Text]

89. Laborde F, Folliguet TA, Etienne PY, Carbognani D, Batisssa A, Petrie J. Video-thorascopic surgical interruption of patent ductus arteriosus: routine experience in 332 pediatric cases. Eur J Cardiothorac Surg. 1997; 11: 1052–1055.[Abstract]

This article has been cited by other articles:

				K DEBL, B DJAVIDANI, S BUCHNER, N HEINICKE, F POSCHENRIEDER, S FEUERBACH, G RIEGGER, and A LUCHNER Quantification of left-to-right shunting in adult congenital heart disease: phase-contrast cine MRI compared with invasive oximetry Br. J. Radiol., May 1, 2009; 82(977): 386 - 391. [Abstract] [Full Text] [PDF]

				M. J. Strickland, M. Klein, A. Correa, M. D. Reller, W. T. Mahle, T. J. Riehle-Colarusso, L. D. Botto, W. D. Flanders, J. A. Mulholland, C. Siffel, et al. Ambient Air Pollution and Cardiovascular Malformations in Atlanta, Georgia, 1986-2003 Am. J. Epidemiol., April 15, 2009; 169(8): 1004 - 1014. [Abstract] [Full Text] [PDF]

				J. M. Dagle, N. T. Lepp, M. E. Cooper, K. L. Schaa, K. J.P. Kelsey, K. L. Orr, D. Caprau, C. R. Zimmerman, K. M. Steffen, K. J. Johnson, et al. Determination of Genetic Predisposition to Patent Ductus Arteriosus in Preterm Infants Pediatrics, April 1, 2009; 123(4): 1116 - 1123. [Abstract] [Full Text] [PDF]

				H. D. Cassidy, L. A. Cassidy, and J. L. Blackshear Incidental Discovery of a Patent Ductus Arteriosus in Adults J Am Board Fam Med, March 1, 2009; 22(2): 214 - 218. [Abstract] [Full Text] [PDF]

				E. Bedard, D. F. Shore, and M. A. Gatzoulis Adult congenital heart disease: a 2008 overview Br. Med. Bull., March 1, 2008; 85(1): 151 - 180. [Abstract] [Full Text] [PDF]

				H. Hasegawa, Y. Yamada, K. Komiyama, M. Hayashi, M. Ishibashi, T. Sunazuka, T. Izuhara, K. Sugahara, K. Tsuruda, M. Masuda, et al. A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy-{Delta}12, 14 prostaglandin J2 production Blood, September 1, 2007; 110(5): 1664 - 1674. [Abstract] [Full Text] [PDF]

				J. H. Shuhaiber and S. Westaby Eisenmenger's Syndrome and Pulmonary-Artery Dissection N. Engl. J. Med., August 16, 2007; 357(7): 718 - 719. [Full Text] [PDF]

This Article Extract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schneider, D. J. Articles by Moore, J. W. Search for Related Content PubMed PubMed Citation Articles by Schneider, D. J. Articles by Moore, J. W. Related Collections Cardiovascular imaging agents/Techniques Pediatric and congenital heart disease, including cardiovascular surgery Cardiac development Epidemiology